Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1727)	12/8/2006 7:19:37 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 3722

Wow, that was fast! I'm sure grateful for your effort and will read your post and examine your charts this weekend. Thanks again!

To: Jibacoa who wrote (1727)	8/8/2007 1:42:58 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MAXY: After forming a base at the $8 level, the stock has been up 14% today. bigcharts.marketwatch.com The up-move is apparently related to Codexis in which MAXY still hold around 33% of the shares, since MAXY's 2nd Q result weren't good. (It reported a net loss of $15.7M or $0.43/shr., vs. loss of $3.4M or $0.09/shr in 2006.)The EL for 2007 is > 2x the $0.72/shr in 2006. Bernard

To: Jibacoa who wrote (1727)	12/11/2007 12:36:32 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

MEDX Is down 20% after it & BMY reported yesterday data from the 3 registrational trials (008, 022, 007) that constitute the monotherapy program for ipilimumab in patients with metastatic melanoma. bigcharts.marketwatch.com The results from study 008, conducted under Special Protocol Assessment (SPA), did not meet the primary endpoint, which was to rule out a best objective response rate of less than 10 percent. However, the totality of data from the registrational program included a clear dose response effect observed in study 022 and best objective response rates across the 3 studies ranging from mid-single digits to mid-teens as determined by independent radiology review. "Given the importance of these findings and the limited treatment options for this patient population, MEDX and BMY are planning to meet with regulatory agencies in the near future. Pending these discussions, the companies aim to submit a regulatory filing to the FDA in the first half of 2008". A CC was scheduled for 8:00 AM today Bernard

To: Jibacoa who wrote (1727)	1/3/2008 4:24:49 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

CRXL also opened with an UG & was up 14.36% at its intraday H, it is still up 12.15% bigcharts.marketwatch.com It announced that it has signed an exclusive agreement with sanofi pasteur, (the vaccines division of sanofi-aventis), for its rabies monoclonal antibodies to be used in association with rabies vaccine for post-exposure prophylaxis. bigcharts.marketwatch.com CRXL Has 4Qs of triple digit improvement on revenues & has trimmed its losses in the last 2Qs. It is trading around 1.7xBV; has no significant LTD. The short position is around 7x its ADV. The stock needs to close above its resistance from the 21.17 to the 22.90 level in order to get off from the DT coming from its Feb H at 29.14 bigcharts.marketwatch.com Bernard